Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial
Official title:
Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease
Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02964273 -
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
|
Phase 3 | |
Terminated |
NCT01223755 -
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
|
Phase 2/Phase 3 | |
Completed |
NCT01280721 -
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
|
Phase 3 | |
Completed |
NCT01214421 -
Tolvaptan Extension Study in Participants With ADPKD
|
Phase 3 | |
Completed |
NCT02225860 -
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01616927 -
Study of Lanreotide to Treat Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT01430494 -
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00346918 -
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
Completed |
NCT03949894 -
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT02925221 -
Canadian Medical Assessment of JINARC™ Outcomes Registry
|
||
Completed |
NCT04689074 -
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
|
||
Terminated |
NCT02616055 -
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
|
Phase 2 | |
Completed |
NCT02112136 -
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD
|
N/A | |
Recruiting |
NCT02115659 -
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
Completed |
NCT00309283 -
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
|
Phase 3 | |
Recruiting |
NCT06345755 -
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants
|
Phase 1 |